biostudies-literatureUnknown17(4)Rubio-Guerra S<h4>Introduction</h4>We previously applied generalized additive models for location, scale, and shape to derive amyloid β-negative next-generation norms (NGN) for a comprehensive neuropsychological battery. Here, we evaluated the accuracy of NGN in detecting cognitive impairment compared to traditional norms (TN).<h4>Methods</h4>This multicenter study included <i>N</i> = 2405 participants classified as cognitively normal (CN, <i>n</i> = 987) or with mild cognitive impairment (MCI, <i>n</i> = 1418) using conventional criteria. All participants underwent neuropsychological testing and cerebrospinal fluid Alzheimer's disease (AD) biomarker assessment. We used actuarial neuropsychological criteria to reclassify all participants using TN and NGN. Diagnostic groups were compared on cognitive perAlzheimer's & dementia (Amsterdam, Netherlands)e70223https://www.ebi.ac.uk/biostudies/studies/S-EPMC12689264biostudies-literatureAmyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies.PMC12689264Llado ARodriguez ERVidela LSanchez-Juan PBejanin AAltuna MTainta MSanchez-Saudinos MBRami LLage CGarcia-Martinez Mde Luis CLAlcolea DSala IGomez-Andres DBalasa MPozueta AZhu NFortea JEcay-Torres MArranz JIllan-Gala ICastellvi MRubio-Guerra SLleo ASanchez-Valle RMartinez-Lage PEstanga ATort-Merino ALopez-Garcia SfalseAmyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies.<h4>Introduction</h4>We previously applied generalized additive models for location, scale, and shape to derive amyloid β-negative next-generation norms (NGN) for a comprehensive neuropsychological battery. Here, we evaluated the accuracy of NGN in detecting cognitive impairment compared to traditional norms (TN).<h4>Methods</h4>This multicenter study included <i>N</i> = 2405 participants classified as cognitively normal (CN, <i>n</i> = 987) or with mild cognitive impairment (MCI, <i>n</i> = 1418) using conventional criteria. All participants underwent neuropsychological testing and cerebrospinal fluid Alzheimer's disease (AD) biomarker assessment. We used actuarial neuropsychological criteria to reclassify all participants using TN and NGN. Diagnostic groups were compared on cognitive per2025-01-01T00:00:00Z2025 Oct-Dec2026-06-06T02:22:28.097Z2026-05-24T03:12:52.752ZS-EPMC126892644138387810.1002/dad2.70223